DGAP-News

MOLOGEN AG: 2013 annual financial statements submitted - pivotal study for MGN1703 under preparation - Seite 3

in colorectal cancer with MGN1703 to the competent authorities in 2014
(IMPALA study). Should the necessary permits be granted in due time, the
company expects to begin this study in the current year. At the same time,
discussions are ongoing with regard to an outlicensing for this product
candidate.

In addition, MOLOGEN is planning the launch of the IMPULSE study for 2014,
a randomized and controlled study with MGN1703 in small cell lung cancer.
Planning and preparation of an advanced clinical trial for MGN1601 is also
scheduled.

As a result of these research activities, MOLOGEN assumes that there will
be a significant increase in the costs of research and development and the
associated outflow of liquid funds in financial year 2014. Overall, the
Executive Board expects another negative annual result. A possible
out-licensing of the drug candidate MGN1703 is not taken into consideration
in this scenario and could have significant positive effects on results and
on the liquidity situation.

Dr. Matthias Schroff, chairman of the Executive Board of MOLOGEN AG says,
"Due to the results we presented relating to the study of our cancer
immunotherapy MGN1703 in the application against colorectal cancer, which
were also well-received in professional circles, we have great faith in the
pivotal study for this product candidate. MOLOGEN is therefore one of the
few biotech companies in Germany which is able to bring a product into a
phase III study completely independently. In addition, the MOLOGEN pipeline
contains other drug candidates, particularly in the field of cancer
immunotherapies, which all have a large market potential. Against this
background, we are very confident with regard to the current financial year
2014."

The complete 2013 annual report of MOLOGEN AG is available for download
from the company's website:
www.mologen.com/en/investor-relations/publications/financial-reports.html


About MOLOGEN AG
MOLOGEN AG is a publicly listed biotechnology company headquartered in
Berlin and specializes in the research and clinical development of
innovative drugs in the fields of oncology and infectious diseases. One of
the company's most important product candidates is the DNA immunomodulator
MGN1703, which is being clinically developed for colorectal cancer and lung
cancer. The cell-based cancer therapy MGN1601 for the treatment of renal
cancer is also currently at the stage of clinical development.

With unique, patented technologies and innovative product developments,
MOLOGEN is one of the leading biotechnology companies in the fields of DNA